NASDAQ:ABVX ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free ABVX Stock Alerts $15.78 +0.04 (+0.25%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$15.06▼$16.0050-Day Range$12.08▼$15.8952-Week Range$7.99▼$17.02Volume53,914 shsAverage Volume47,256 shsMarket Capitalization$993.04 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get ABIVAX Société Anonyme alerts: Email Address ABIVAX Société Anonyme MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside14.1% Upside$18.00 Price TargetShort InterestHealthy0.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.40) to ($2.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.33 out of 5 starsMedical Sector725th out of 915 stocksPharmaceutical Preparations Industry333rd out of 424 stocks 2.3 Analyst's Opinion Consensus RatingABIVAX Société Anonyme has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageABIVAX Société Anonyme has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.19% of the float of ABIVAX Société Anonyme has been sold short.Short Interest Ratio / Days to CoverABIVAX Société Anonyme has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABIVAX Société Anonyme has recently decreased by 29.54%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldABIVAX Société Anonyme does not currently pay a dividend.Dividend GrowthABIVAX Société Anonyme does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABVX. Previous Next 2.8 News and Social Media Coverage News SentimentABIVAX Société Anonyme has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ABIVAX Société Anonyme this week, compared to 2 articles on an average week.Search Interest2 people have searched for ABVX on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ABIVAX Société Anonyme insiders have not sold or bought any company stock.Percentage Held by Institutions47.91% of the stock of ABIVAX Société Anonyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ABIVAX Société Anonyme are expected to decrease in the coming year, from ($2.40) to ($2.88) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About ABIVAX Société Anonyme Stock (NASDAQ:ABVX)ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Read More ABVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABVX Stock News HeadlinesApril 27, 2024 | americanbankingnews.comABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Down 29.5% in AprilApril 10, 2024 | seekingalpha.comABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call TranscriptApril 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 10, 2024 | seekingalpha.comABVX ABIVAX Société AnonymeApril 2, 2024 | globenewswire.comAbivax reports 2023 financial results and operational updateMarch 14, 2024 | morningstar.comAbivax SA ADR ABVXFebruary 23, 2024 | wsj.comAbivax S.A. ADRFebruary 20, 2024 | finance.yahoo.comABIVAX Société Anonyme (ABVX.PA)April 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 17, 2024 | morningstar.comAbivax SA ABVXFebruary 13, 2024 | finance.yahoo.comAbivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)January 29, 2024 | finance.yahoo.comAbivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq ListingJanuary 29, 2024 | finance.yahoo.comAbivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price RangeJanuary 29, 2024 | finance.yahoo.comAbivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext ParisJanuary 29, 2024 | finance.yahoo.comAbivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global MarketJanuary 29, 2024 | finance.yahoo.comAbivax Announces Trading Resumption of its Ordinary Shares on Euronext ParisJanuary 29, 2024 | finance.yahoo.comAbivax Announces Closing of its Initial Public Offering on the Nasdaq Global MarketSee More Headlines Receive ABVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABIVAX Société Anonyme and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABVX Previous SymbolNASDAQ:ABVX CUSIPN/A CIK1956827 Webwww.abivax.com Phone33-1-53-83-09-63FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$20.00 Low Stock Price Target$16.00 Potential Upside/Downside+14.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares62,930,000Free FloatN/AMarket Cap$993.04 million OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Marc M. P. de Garidel M.B.A. (Age 66)CEO & Interim Chair of Board Comp: $843.59kDr. Philippe Pouletty M.D. (Age 66)Ph.D., Founder & Director Mr. Didier Blondel (Age 60)EVP, CFO & Board Secretary Mr. Didier Scherrer Ph.D. (Age 54)Chief Scientific Officer Mr. Patrick MalloySenior Vice President of Investor RelationsMs. Ida Hatoum (Age 49)Chief People Officer Mr. Pierre Courteille M.B.A. (Age 55)Chief Business Officer Mr. Jérôme DenisExecutive Vice President of Process Development & ManufacturingMr. Sheldon Sloan M.D. (Age 65)Chief Medical Officer Mr. Michael Ferguson B.S. (Age 46)M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsInnovivaNASDAQ:INVALiquidiaNASDAQ:LQDACassava SciencesNASDAQ:SAVAMacroGenicsNASDAQ:MGNXCentessa PharmaceuticalsNASDAQ:CNTAView All CompetitorsInstitutional OwnershipRosalind Advisors Inc.Bought 378,416 shares on 4/25/2024Ownership: 0.601%Blackstone Inc.Bought 2,368,722 shares on 2/15/2024Ownership: 3.764%Great Point Partners LLCBought 1,550,000 shares on 2/15/2024Ownership: 2.463%Commodore Capital LPBought 1,895,003 shares on 2/14/2024Ownership: 3.011%Ghisallo Capital Management LLCBought 60,000 shares on 2/14/2024Ownership: 0.095%View All Institutional Transactions ABVX Stock Analysis - Frequently Asked Questions Should I buy or sell ABIVAX Société Anonyme stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ABIVAX Société Anonyme in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABVX shares. View ABVX analyst ratings or view top-rated stocks. What is ABIVAX Société Anonyme's stock price target for 2024? 3 equities research analysts have issued 12-month target prices for ABIVAX Société Anonyme's stock. Their ABVX share price targets range from $16.00 to $20.00. On average, they anticipate the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 14.1% from the stock's current price. View analysts price targets for ABVX or view top-rated stocks among Wall Street analysts. How have ABVX shares performed in 2024? ABIVAX Société Anonyme's stock was trading at $10.70 at the beginning of the year. Since then, ABVX shares have increased by 47.5% and is now trading at $15.78. View the best growth stocks for 2024 here. Are investors shorting ABIVAX Société Anonyme? ABIVAX Société Anonyme saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 113,800 shares, a decrease of 29.5% from the March 31st total of 161,500 shares. Based on an average daily trading volume, of 74,700 shares, the short-interest ratio is presently 1.5 days. Currently, 0.2% of the company's stock are sold short. View ABIVAX Société Anonyme's Short Interest. When did ABIVAX Société Anonyme IPO? ABIVAX Société Anonyme (ABVX) raised $217 million in an initial public offering (IPO) on Friday, October 20th 2023. The company issued 18,699,460 shares at a price of $11.60 per share. When did ABIVAX Société Anonyme's lock-up period expire? ABIVAX Société Anonyme's lock-up period expired on Wednesday, April 17th. ABIVAX Société Anonyme had issued 18,699,460 shares in its public offering on October 20th. The total size of the offering was $216,913,736 based on an initial share price of $11.60. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period. Who are ABIVAX Société Anonyme's major shareholders? ABIVAX Société Anonyme's stock is owned by many different institutional and retail investors. Top institutional shareholders include Rosalind Advisors Inc. (0.60%). How do I buy shares of ABIVAX Société Anonyme? Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABVX) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe World's First "$20 Trillion Drug?"Behind the Markets4 Cryptos BETTER than BitcoinTrue Market InsidersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABIVAX Société Anonyme Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
